DOCSLIB.ORG

Corporate Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Corporate Update ® Developing Breakthrough Biologics, Life-changing Medicines Corporate Update September 2019 Legal Notices The information in this slide deck is current as of August 31, 2019, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements Any statements in these materials about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of the Company’s therapeutic candidates, milestone or opt-in payments from the Company’s collaborators, the Company’s anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company’s filings with the Securities and Exchange Commission. In addition, the forward- looking statements included in this presentation represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward- looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Trademarks DART, TRIDENT, MacroGenics, the MacroGenics logo and “Breakthrough Biologics, Life-Changing Medicines” are trademarks or registered trademarks of MacroGenics, Inc. The Incyte logo is a registered trademark of Incyte Corporation. Investigational Agents All Company product candidates described or mentioned herein are investigational and have not yet been approved for marketing by any regulatory authority. 2 September 2019 Committed to Developing Life-changing Medicines Innovative Combinatorial Approaches Resourced for Success Nine immuno-oncology clinical candidates $272M Cash @ 06/30/19(a) Multiple alliances with Fc optimization platform to enhance antibodies’ immune activation leading biopharma companies Commercial scale GMP Leading bispecific DART® platform to exploit multiple mechanisms manufacturing facility ~380 Employees Multi-program “franchises” around high-value targets (B7-H3, PD-1) (Rockville, MD & SF Bay Area) (a) Includes cash equivalents and marketable securities. 3 September 2019 Broad Array of Engineered Antibody Formats Engaging the Immune System to Target Cancer Fc-Optimized Antibody Drug Antibody DART/TRIDENT™ Molecules Antibody Conjugate Bivalent Bivalent Bivalent Bivalent Tetravalent Trivalent Monospecific Monospecific Monospecific Bispecific Bispecific Trispecific Fab Region Fc Region Key Features: • Enhance Fc-mediated • Leverage 3rd party • “Plug-and-play” multi-specific platforms activity, incl. ADCC linker-payload tech • Tailored half-life and avidity/valency to optimize product profile • Promote innate and (Synthon, Immunogen) • Broad range of modalities pursued: adaptive immunity • Deliver potent anti- – Co-blockade of multiple checkpoint molecules • Combine with tumor payload – Redirect T-cell killing checkpoint inhibitors – to augment activity Tumor-directed co-stimulation 4 September 2019 Our Advancing Immuno-Oncology Pipeline Retains major market commercial rights for 8 of 9 development candidates Program (Target) Potential Indication Pre-IND Phase 1 Phase 2 Phase 3 Collaborator Our Commercial Rights Margetuximab (HER2) Breast (HER2+) “SOPHIA” Zai Lab, Worldwide, excluding South Korea GC Pharma and Greater China Gastric (+anti-PD-1) Enoblituzumab (B7-H3) Solid Tumors (+anti-PD-1) I-Mab Biopharma Worldwide, excluding Greater China H3 - MGD009 (B7-H3 × CD3) Solid Tumors (+MGA012) — Worldwide B7 MGC018 (B7-H3)(a) Solid Tumors — Worldwide MGA012 (PD-1) Solid Tumors Incyte(b) — 1 - MGD013 (PD-1 × LAG-3) Solid Tumors/Heme Mal. Zai Lab Worldwide, excluding Greater China PD MGD019 (PD-1 × CTLA-4) Solid Tumors — Worldwide Flotetuzumab (CD123 × CD3) AML — Worldwide AML (+MGA012) MGD007 (gpA33 × CD3) Colorectal (+MGA012) — Worldwide “MGD” = DART “MGA” = Antibody “MGC” = ADC (a) MGC018 is an antibody-drug conjugate (ADC) based on a duocarmycin payload with cleavable peptide linker that was licensed from Synthon Biopharmaceuticals. (b) MacroGenics retains rights to develop its pipeline assets in combination w/MGA012 (INCMGA0012) and to manufacture a portion of global clinical and commercial supply needs of MGA012. All Company product candidates described or mentioned herein are investigational and have not yet been approved for marketing by any regulatory authority. 5 September 2019 Core Product Candidates with Key Milestones Anticipated in 2019 Enhance Innate Margetuximab Enoblituzumab Immune Function (Anti-HER2 mAb) (Anti-B7-H3 mAb) through Fc Optimization (a) Restore and MGA012 MGD013 Flotetuzumab Redirect T-Cell (Anti-PD-1 mAb) (PD-1 × LAG-3 DART) (CD123 × CD3 DART) Function (a) MacroGenics retains rights to develop its pipeline assets in combination with MGA012 (INCMGA0012) and to manufacture a portion of global clinical and commercial supply needs of MGA012. 6 September 2019 Building Competitive Advantage Around Combinatorial Mechanisms Tumor Destruction Restore T-Cell Function: Enhance T-cell Function: and Antigen Presentation Checkpoint Inhibition T-Cell Recruitment Complementary MOA’s Complementary MOA’s MGA012 Flotetuzumab Margetuximab or Enoblituzumab MGD013 TAA: tumor-associated antigen 7 September 2019 Margetuximab Margetuximab: Anti-HER2 mAb Engineered to Enhance Activity of Immune System Positive results from pivotal phase 3 study presented at ASCO 2019 • Inhibits HER2 signaling (similar to trastuzumab) Function/ • MoA Fc region engineered to engage innate and adaptive immunity as mediators of anti-tumor activity HER2 HER2 • Ph. 3 SOPHIA study in HER2+ metastatic breast cancer Fab Pivotal Region Clinical • Ph. 2/3 MAHOGANY study w/checkpoint inhibitor in Studies HER2+ gastric cancer (anticipated start 3Q19) • Ph. 3 SOPHIA study ‒ Positive PFS results reported ASCO 2019 Fc Region Program ‒ Interim OS results expected 4Q19, final OS in 2020 Status • BLA submission in HER2+ mBC expected 4Q19 • Ph. 1 HER2+ gastric cancer data reported ASCO GI 2019 MacroGenics’ Retained • Global rights (excl. Greater China, South Korea) Rights Margetuximab is investigational and has not yet been approved for marketing by any regulatory authority 8 September 2019 Margetuximab 3rd/4th Line HER2+ Metastatic Breast Cancer Represents Attractive Entry Point mBC Line of Therapy 1st Line 2nd Line 3rd/4th Line Annual # of Patients(a) ~19,200 ~16,000 ~18,800 No consensus Trastuzumab T-DM1 (lapatinib + capecitabine; Standard of Care + pertuzumab (ado-trastuzumab trastuzumab + different + taxane (docetaxel) emtansine) chemo) Median OS 56.5 months(b) 30.9 months(c) 15.8 months(d) Median PFS 18.5 months(b) 9.6 months(c) 3.3 months(e) ORR 80.2%(b) 43.6%(c) 8.6% (a) US/EU5 Data from 9/13/18 Roche Virtual Late Stage Pipeline Event (b) Baselga, et al. – CLEOPATRA Study Group; Perjeta package insert (c) Verma, et al. – EMILIA Study Group; Kadcyla package insert (d) Krop, et al., The Lancet (June 2017) – TH3RESA Study Group (e) Krop, et al., The Lancet (May 2014) – TH3RESA Study Group 9 September 2019 Margetuximab Phase 3 Study Comparing Margetuximab to Trastuzumab SOPHIA clinical trial designed to support registration in 3rd/4th line HER2+ metastatic breast cancer Arm 1 margetuximab + HER2+ mBC Investigator’s Choice of chemotherapy 1–3 Prior Treatment Lines Chemotherapy in Metastatic Setting 1:1 Randomization (N = 536) (capecitabine, eribulin, R (including prior treatment with gemcitabine or vinorelbine) multiple other anti-HER2 agents)(a) Arm 2 trastuzumab + chemotherapy • Sequential primary endpoints: PFS and OS − PFS and first interim OS analyses as of October 2018 − Second interim OS analysis planned at 270 events in 2H2019 − Final OS analysis planned at 385 events in 2020 Global sites: ~200 • Patients carrying CD16A (FcγRIIIa) 158F allele were pre-specified PFS (N=257, HR=0.67, α=0.05, power=90%) exploratory subpopulation OS (N=385, HR=0.75, α=0.05, power=80%) (a) All study patients had previously received trastuzumab and pertuzumab, and approximately 90% had previously received ado-trastuzumab emtansine. 10 September 2019 Margetuximab SOPHIA Ph. 3 Demonstrated Superiority to Trastuzumab in Primary PFS Endpoint PFS prolonged in margetuximab arm vs. trastuzumab arm PFS Primary Endpoint (ITT Population):
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • PD-1 / PD-L1 Combination Therapies
    PD-1 / PD-L1 Combination Therapies Jacob Plieth & Edwin Elmhirst – May 2017 Foreword Sprinkling the immuno-oncology dust When in November 2015 EP Vantage published its first immuno- oncology analysis we identified 215 studies of anti-PD-1/PD-L1 projects combined with other approaches, and called this an important industry theme. It is a measure of how central combos have become that today, barely 18 months on, that total has been blown out of the water. No fewer than 765 studies involving combinations of PD-1 or PD-L1 assets are now listed on the Clinicaltrials.gov registry. This dazzling array owes much to the transformational nature of the data seen with the first wave of anti-PD-1/PD-L1 MAbs. It also indicates how central combinations will be in extending immuno-oncology beyond just a handful of cancers, and beyond certain patient subgroups. But the combo effort is as much about extending the reach of currently available drugs like Keytruda, Opdivo and Tecentriq as it is about making novel approaches viable by combining them with PD-1/PD-L1. On a standalone basis several of the industry’s novel oncology projects have underwhelmed. As data are generated it will therefore be vital for investors to tease out the effect of combinations beyond that of monotherapy, and it is doubtful whether the sprinkling of magic immuno-oncology dust will come to the rescue of substandard products. This is not stopping many companies, as the hundreds of combination studies identified here show. This report aims to quantify how many trials are ongoing with which assets and in which cancer indications, as well as suggesting reasons why some of the most popular approaches are being pursued.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • Flotetuzumab: CD123 × CD3 DART Molecule
    ® Breakthrough Biologics, Life-changing Medicines Corporate Update January 6, 2019 Legal Notices The information in this slide deck is current as of January 6, 2019, unless otherwise noted. The information in this slide deck is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements Any statements in these materials about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of the Company’s therapeutic candidates, milestone or opt-in payments from the Company’s collaborators, the Company’s anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company’s filings with the Securities and Exchange Commission.
    [Show full text]
  • 2018 Jp Morgan Healthcare Conference: Review
    Click here8 to JP request Morgan a demonstration Healthcare of Biomedtracker Conference Review Cover page, paste image over entire page 201 8 JP MORGAN HEALTHCARE CONFERENCE: REVIEW January 2018 / 1 2018 JP Morgan Healthcare Conference Review Summary The 36th annual JP Morgan Healthcare Conference was held in San Francisco, CA from January 8-11, 2018. A full list of events and catalysts that were announced or updated during the conference is included in this report. Below are our key points from the conference’s company presentations. Key Points – Conference Review Large/Mega Cap Companies • The meeting was kicked off by Celgene (CELG), who followed their overnight announcement of acquiring Impact Biomedicines and its late-stage myelofibrosis asset fedratinib in a deal worth $1.1bn up-front and up to an additional $5.9bn in regulatory and sales-based milestone payments. While some question the value of the drug, which earlier had safety concerns but is now expected to be submitted mid-2018, the company hopes it will help build its leadership in myelofibrosis, addressing important unmet needs in patients intolerant or resistant to the current standard of care Jakafi. It could also be used in potential combinations with the company's investigational luspatercept to address first-line myelofibrosis patients that co-present with anemia. Celgene’s Q4 2017 revenue of $3.48bn was up 17% compared to the previous year, generally within expectations. Growth has been primarily driven by the continued uptake of key products Revlimid, Pomalyst and Otezla with Celgene reporting revenues in 2017 of $8.2bn (up 17.4% compared to 2016), $1.6bn (23.1%) and $1.3bn (25.7%), respectively.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • 2018 Medicines in Development for Cancer
    2018 Medicines in Development for Cancer Bladder Cancer Product Name Sponsor Indication Development Phase ABI-009 AADi Bioscience non-muscle invasive bladder cancer Phase I/II (nab-rapamycin/mTOR inhibitor) Los Angeles, CA www.aadibio.com ALT-801 Altor BioScience non-muscle invasive bladder cancer Phase I/II (tumor antigen-specific T-cell Miramar, FL www.altorbioscience.com receptor linked to IL-2) NantKwest Culver City, CA ALT-803 Altor BioScience non-muscle invasive bladder cancer Phase II (IL-15 superagonist protein complex) Miramar, FL (BCG naïve) (Fast Track), www.altorbioscience.com NantKwest non-muscle invasive bladder cancer Culver City, CA (BCG unresponsive) (Fast Track) B-701 BioClin Therapeutics 2L locally advanced or metastatic Phase I/II (anti-FGFR3 mAb) San Ramon, CA bladder cancer www.bioclintherapeutics.com Bavencio® EMD Serono 1L urothelial cancer Phase III avelumab Rockland, MA www.emdserono.com (anti-PD-L1 inhibitor) Pfizer www.pfizer.com New York, NY BC-819 BioCanCell Therapeutics non-muscle invasive bladder cancer Phase II (gene therapy) Cambridge, MA (Fast Track) www.biocancell.com Medicines in Development: Cancer ǀ 2018 1 Bladder Cancer Product Name Sponsor Indication Development Phase Capzola® Spectrum Pharmaceuticals non-muscle invasive bladder cancer application submitted apaziquone Henderson, NV (Fast Track) www.sppirx.com Cavatak® Viralytics bladder cancer (+pembrolizumab) Phase I coxsackievirus Sydney, Australia www.viralytics.com CG0070 Cold Genesys non-muscle invasive bladder cancer Phase II (oncolytic immunotherapy)
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • International Nonproprietary Names for Pharmaceutical Substances (INN)
    WHO Drug Information, Vol. 31, No. 1, 2017 Recommended INN: List 77 International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 77 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–113) and Recommended (1–74) International Nonproprietary Names can be found in Cumulative List No. 16, 2015 (available in CD-ROM only). Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES: Liste 77 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–113) et recommandées (1–74) dans la Liste récapitulative No.
    [Show full text]